Daniel P. Petrylak, MD

Prostate cancer advancements highlight genetic mutations' impact on therapy and family health, emphasizing early treatment strategies for better outcomes.

Dr Daniel Petrylak discusses groundbreaking advancements in prostate cancer treatment, including genetic mutations, PARP inhibitors, and innovative PROTAC therapies.

Discover groundbreaking advancements in prostate cancer treatment with innovative PROTAC drugs, promising new trials, and enhanced therapy effectiveness.

Navigating the complex landscape of prostate cancer treatment sequencing is crucial for maximizing patient outcomes and survival rates.

Daniel P. Petrylak, MD, discusses the design and results of the TITAN trial of apalutamide in patients with metastatic castration-sensitive prostate cancer.

Daniel P. Petrylak, MD, discusses the impact of the approval of apalutamide in the metastatic castration-sensitive prostate cancer setting.

Daniel P. Petrylak, MD, discusses the efficacy results from the CARD trial, which evaluated the radiographic progression-free survival of cabazitaxel combined with either abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer.<br /> &nbsp;

Daniel P. Petrylak, MD, discusses the data from the phase II EV-201 trial investigating enfortumab vedotin as treatment of patients with locally advanced or metastatic urothelial cancer previously treated with platinum-based chemotherapy or a PD-1/PD-L1 checkpoint inhibitor.

Daniel P. Petrylak, MD, a professor of Medicine and Urology and co-director of the Signal Transduction Research Program at Yale School of Medicine, discussed results from the phase III RANGE trial for the combination of ramucirumab (Cyramza) and docetaxel in patients with urothelial carcinoma.

Daniel P. Petrylak, MD,&nbsp;professor of Medicine and Urology, Yale Cancer Center, discusses studies evaluating second-line treatment options in bladder cancer.

Daniel P. Petrylak, MD, talks about taking the clinical trials examining MPDL3280A a step further for bladder cancer patients.

Daniel P. Petrylak, MD, professor of Medicine (Medical Oncology) and of Urology, co-director, Signal Transduction Research Program, Yale Cancer Center, discusses bacillus calmette-guerin (BCG) therapy for the treatment of patients with non-invasive bladder cancer.

Daniel P. Petrylak, MD, discusses the results of the phase II STRIDE study in metastatic castration-resistant prostate cancer (mCRPC).

Daniel P. Petrylak, MD, discusses a phase II trial of prostate specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-treated metastatic castration-resistant prostate cancer (mCRPC).

Daniel P. Petrylak, MD, director, Prostate and GU Medical Oncology, Yale Cancer Center, discusses sequencing agents in prostate cancer.

Daniel P. Petrylak, MD, director, Prostate and GU Medical Oncology, Yale Cancer Center, discusses PSMA and its role in prostate cancer treatment.

Daniel P. Petrylak, MD, director, Prostate and GU Medical Oncology, Yale Cancer Center, describes imaging approaches in prostate cancer.